Business
Arrowhead Pharmaceuticals develops RNA-interference medicines.
Arrowhead Pharmaceuticals grew revenue, reported a net loss, generated positive free cash flow at a 11.9% operating margin. Revenue was partnership-driven and net income near break-even; positive free cash flow did not remove clinical concentration risk.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 23258.2%OK
- Profitability — The net loss narrowed from $599.493M to $1.631MOK
- Cash flow — Free cash flow turned positive at $156.886M from an outflow of $604.32MOK
- Margins — Operating margin was 11.86%Note
- Accounting — Revenue was partnership-driven and net income near break-evenWatch
- Insiders — 0 purchases and 24 salesWatch
Where the revenue comes from
Fiscal 2025, as ARROWHEAD PHARMACEUTICALS, INC. reports it. History and quarterly detail are in the app.
- Sanofi License Agreement$130.0M
Leadership changes
From ARROWHEAD PHARMACEUTICALS, INC.'s own filings, the day they're filed.
- Matt Cohen · Director · appointmenteff. 2026-06-12
- Ken Myszkowski · Chief Financial Officer · departureeff. 2025-05-13
- Douglas Ingram · Director · appointmenteff. 2025-02-06
Latest filings
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-05-07
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ARROWHEAD PHARMACEUTICALS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.